Clinical Trial Update: Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy [Phase 2]

View source ↗

Summary

Phase 2 study comparing pemetrexed plus bortezomib, pemetrexed alone, or bortezomib alone in locally advanced or metastatic non-small cell lung cancer after pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED